(Updated - July 19, 2016 4:23 PM EDT)

Sarepta Therapeutics (NASDAQ: SRPT) reported Q2 EPS of ($1.35), versus the analyst estimate of ($1.23).

For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.

Earnings

Oppenheimer Continues to Expect Sarepta (SRPT) Eteplirsen Approval in the Next Few MonthsJuly 20, 2016 9:48 AM Form 8-K Sarepta Therapeutics, For: Jul 19July 19, 2016 4:06 PM Sarepta Therapeutics Announces Second Quarter 2016 Financial Results and Recent Corporate DevelopmentsJuly 19, 2016 4:00 PM Stocks with Implied Volatility MovementJuly 18, 2016 5:11 AM Santhera's Lack of FDA Support is not a Read Through for Sarepta Therapeutics (SRPT) - OppenheimerJuly 15, 2016 10:58 AM